

Paul B Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8208037/publications.pdf>

Version: 2024-02-01

103
papers

7,792
citations

61984
43
h-index

51608
86
g-index

110
all docs

110
docs citations

110
times ranked

8689
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Link in the Chain: Unspliced XBP1 in Wnt Signaling and Vascular Calcification. Circulation Research, 2022, 130, 230-233.	4.5	4
2	Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Scientific Reports, 2022, 12, 7803.	3.3	26
3	Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1. Journal of Clinical Investigation, 2022, 132, .	8.2	17
4	Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart. Circulation Research, 2022, 130, 1445-1465.	4.5	10
5	Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP). BMC Musculoskeletal Disorders, 2022, 23, .	1.9	3
6	Circulating BMP9 Protects the Pulmonary Endothelium during Inflammation-induced Lung Injury in Mice. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1419-1430.	5.6	34
7	BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma. Stem Cells and Development, 2021, 30, 91-105.	2.1	17
8	Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva. Orphanet Journal of Rare Diseases, 2021, 16, 54.	2.7	4
9	Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight, 2021, 6, .	5.0	29
10	A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification. Science Translational Medicine, 2021, 13, .	12.4	16
11	Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G>AA in the ACVR1 gene. Stem Cell Research, 2021, 54, 102424.	0.7	0
12	Sotatercept for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 385, 92-93.	27.0	10
13	Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Frontiers in Endocrinology, 2021, 12, 732728.	3.5	15
14	Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
15	Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. Journal of Heart and Lung Transplantation, 2020, 39, 289-299.	0.6	19
16	Periostin. Circulation Research, 2020, 127, 1153-1155.	4.5	2
17	The role of bone morphogenetic protein signaling in vascular calcification. Bone, 2020, 141, 115542.	2.9	72
18	Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells. Angiogenesis, 2020, 23, 699-714.	7.2	22

#	ARTICLE	IF	CITATIONS
19	A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nature Communications, 2020, 11, 2289.	12.8	48
20	ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Science Translational Medicine, 2020, 12, .	12.4	98
21	Perspectives on Cardiopulmonary Critical Care for Patients With COVID-19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Journal of the American Heart Association, 2020, 9, e017111.	3.7	5
22	Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren's syndrome in mice. Scientific Reports, 2020, 10, 2967.	3.3	17
23	BMP9/10 in Pulmonary Vascular Complications of Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1575-1578.	5.6	32
24	Bone Morphogenetic Protein-2 Induces Non-Canonical Inflammatory and Oxidative Pathways in Human Retinal Endothelial Cells. Frontiers in Immunology, 2020, 11, 568795.	4.8	10
25	Finding the Target: In Silico and Genetic Screening for Mechanistically Novel Drugs in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 9-11.	5.6	12
26	ST-Segment Elevation Myocardial Infarction Due to Right Coronary Artery Compression by Cardiac Synovial Sarcoma. JACC: Cardiovascular Interventions, 2019, 12, e145-e147.	2.9	2
27	Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). Frontiers in Pharmacology, 2019, 10, 234.	3.5	7
28	Letter by Morrell et al Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension". Circulation Research, 2019, 124, e81.	4.5	2
29	Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials. PLoS ONE, 2019, 14, e0211909.	2.5	7
30	Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossification. Bone Research, 2019, 7, 36.	11.4	37
31	In Search of the Second Hit in Pulmonary Arterial Hypertension. Circulation Research, 2019, 124, 6-8.	4.5	12
32	Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 891-902.	5.6	69
33	Pharmacologic Strategies for Assaying BMP Signaling Function. Methods in Molecular Biology, 2019, 1891, 221-233.	0.9	5
34	Update in Pulmonary Vascular Disease 2016 and 2017. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 13-23.	5.6	6
35	The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Bone, 2018, 109, 210-217.	2.9	45
36	Room With a View. Circulation: Cardiovascular Imaging, 2018, 11, e008148.	2.6	1

#	ARTICLE	IF	CITATIONS
37	Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3356-3362.	2.2	19
38	Career Development of Young Physicianâ€“Scientists in the Cardiovascular Sciences. Circulation Research, 2018, 122, 1330-1333.	4.5	6
39	NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Science Translational Medicine, 2018, 10, .	12.4	89
40	The traumatic bone: trauma-induced heterotopic ossification. Translational Research, 2017, 186, 95-111.	5.0	95
41	Bone Morphogenetic Protein Signaling in Pulmonary Arterial Hypertension. , 2017, , 293-326.		0
42	Reestablishment of Energy Balance in a Male Mouse Model With POMC Neuron Deletion of BMPR1A. Endocrinology, 2017, 158, 4233-4245.	2.8	12
43	Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification. Molecular Therapy, 2017, 25, 1974-1987.	8.2	57
44	The Role of Bone Marrowâ€“derived Cells in Pulmonary Arterial Hypertension. What Lies Beneath?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 822-824.	5.6	3
45	A Selective Transforming Growth Factor-Î² Ligand Trap Attenuates Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1140-1151.	5.6	109
46	Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Science Translational Medicine, 2016, 8, 366ra163.	12.4	168
47	Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation. Journal of Visualized Experiments, 2016, , .	0.3	19
48	Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1410-1420.	5.6	77
49	Upâ€“regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB Journal, 2016, 30, 2511-2527.	0.5	39
50	Targeting BMP signalling in cardiovascular disease and anaemia. Nature Reviews Cardiology, 2016, 13, 106-120.	13.7	193
51	Animal Models of Pulmonary Hypertension. , 2016, , 161-172.		2
52	Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension. Pulmonary Circulation, 2016, 6, 498-507.	1.7	15
53	Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation. Haematologica, 2015, 100, e68-e71.	3.5	35
54	Contributions of Muscle-Resident Progenitor Cells to Homeostasis and Disease. Current Molecular Biology Reports, 2015, 1, 175-188.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 236-241.	2.1	12
56	Elafin in Pulmonary Arterial Hypertension. Beyond Targeting Elastases. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1217-1219.	5.6	5
57	Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nature Medicine, 2015, 21, 777-785.	30.7	389
58	<i>ACVR1</i> ^{R206H} receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Science Translational Medicine, 2015, 7, 303ra137.	12.4	366
59	Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells. Cardiovascular Research, 2015, 108, 278-287.	3.8	73
60	Excess placental secreted frizzled-related protein 1 in maternal smokers impairs fetal growth. Journal of Clinical Investigation, 2015, 125, 4021-4025.	8.2	18
61	Inhibition of Bone Morphogenetic Protein Signal Transduction Prevents the Medial Vascular Calcification Associated with Matrix Gla Protein Deficiency. PLoS ONE, 2015, 10, e0117098.	2.5	58
62	Specific Activin Receptor-Like Kinase 3 Inhibitors Enhance Liver Regeneration. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 549-558.	2.5	24
63	C-terminal Domain (CTD) Small Phosphatase-like 2 Modulates the Canonical Bone Morphogenetic Protein (BMP) Signaling and Mesenchymal Differentiation via Smad Dephosphorylation. Journal of Biological Chemistry, 2014, 289, 26441-26450.	3.4	32
64	Structure-Activity Relationship of 3,5-Diaryl-2-aminopyridine ALK2 Inhibitors Reveals Unaltered Binding Affinity for Fibrodysplasia Ossificans Progressiva Causing Mutants. Journal of Medicinal Chemistry, 2014, 57, 7900-7915.	6.4	84
65	The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. Blood, 2014, 123, 2261-2268.	1.4	56
66	HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression. Blood, 2014, 124, 1335-1343.	1.4	110
67	Abstract 17285: A Selective Transforming Growth Factor- β 2 and Growth Differentiation Factor-15 Ligand Trap Attenuates Pulmonary Hypertension. Circulation, 2014, 130, .	1.6	1
68	Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor. ACS Chemical Biology, 2013, 8, 1291-1302.	3.4	131
69	Constitutively Active ALK2 Receptor Mutants Require Type II Receptor Cooperation. Molecular and Cellular Biology, 2013, 33, 2413-2424.	2.3	85
70	Circulating Angiogenic Modulatory Factors Predict Survival and Functional Class in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 369-380.	1.7	56
71	β -Np63 β -Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells. Cancer Research, 2013, 73, 1020-1030.	0.9	55
72	Augmentation of smad-dependent BMP signaling in neural crest cells causes craniosynostosis in mice. Journal of Bone and Mineral Research, 2013, 28, 1422-1433.	2.8	88

#	ARTICLE	IF	CITATIONS
73	A New Class of Small Molecule Inhibitor of BMP Signaling. PLoS ONE, 2013, 8, e62721.	2.5	219
74	Oral Administration Of a BMP Type I Receptor Inhibitor Prevents The Development Of Anemia Of Inflammation. Blood, 2013, 122, 2195-2195.	1.4	3
75	Inhibition of Bone Morphogenetic Protein Signaling Reduces Vascular Calcification and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 613-622.	2.4	188
76	Hepcidin Regulation by BMP Signaling in Macrophages Is Lipopolysaccharide Dependent. PLoS ONE, 2012, 7, e44622.	2.5	31
77	Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood, 2011, 117, 4915-4923.	1.4	161
78	Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood, 2011, 118, 4224-4230.	1.4	161
79	Alk3, a BMP Type I Receptor Is Required for the Induction of Hepatic Hepcidin Gene Expression by Interleukin-6. Blood, 2011, 118, 686-686.	1.4	18
80	Wnt inhibitors <i>Dkk1</i> and <i>Sost</i> are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. Journal of Bone and Mineral Research, 2010, 25, 200-210.	2.8	190
81	Takotsubo Cardiomyopathy Complicated by Cardiac Tamponade. Circulation, 2010, 122, 1239-1241.	1.6	21
82	Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. International Journal of Biochemistry and Cell Biology, 2010, 42, 1802-1807.	2.8	132
83	Role of BMP Signaling In the Anemia of Chronic Disease. Blood, 2010, 116, 2043-2043.	1.4	0
84	Transforming Growth Factor β 2 Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenetic Protein Receptors. Journal of Biological Chemistry, 2009, 284, 9755-9763.	3.4	115
85	p63 Suppresses Non-epidermal Lineage Markers in a Bone Morphogenetic Protein-dependent Manner via Repression of Smad7. Journal of Biological Chemistry, 2009, 284, 30574-30582.	3.4	35
86	Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva. Journal of Biological Chemistry, 2009, 284, 7149-7156.	3.4	184
87	Applications of small molecule BMP inhibitors in physiology and disease. Cytokine and Growth Factor Reviews, 2009, 20, 409-418.	7.2	103
88	Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4388-4392.	2.2	307
89	Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nature Chemical Biology, 2008, 4, 33-41.	8.0	930
90	BMP type I receptor inhibition reduces heterotopic ossification. Nature Medicine, 2008, 14, 1363-1369.	30.7	559

#	ARTICLE	IF	CITATIONS
91	Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for BMP-mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 3877-3888.	3.4	86
92	Dorsomorphin, a Selective Small Molecule Inhibitor of BMP Signaling, Promotes Cardiomyogenesis in Embryonic Stem Cells. <i>PLoS ONE</i> , 2008, 3, e2904.	2.5	188
93	Repulsive Guidance Molecule RGMa Alters Utilization of Bone Morphogenetic Protein (BMP) Type II Receptors by BMP2 and BMP4. <i>Journal of Biological Chemistry</i> , 2007, 282, 18129-18140.	3.4	91
94	Left Atrial Esophageal Fistula After Pulmonary Vein Isolation. <i>Circulation</i> , 2007, 115, e432-3.	1.6	24
95	Sensitization with Xenogeneic Tissues Alters the Heavy Chain Repertoire of Human Anti-Gal α 1-3Gal Antibodies. <i>Transplantation</i> , 2005, 80, 102-109.	1.0	9
96	Bone Morphogenetic Protein (BMP) Type II Receptor Deletion Reveals BMP Ligand-specific Gain of Signaling in Pulmonary Artery Smooth Muscle Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 24443-24450.	3.4	190
97	BMPRII heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 287, L1241-L1247.	2.9	186
98	Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab). <i>Clinical Immunology</i> , 2001, 98, 175-179.	3.2	67
99	BIOPHYSICAL CHARACTERISTICS OF ANTI-GAL α 1-3GAL IgM BINDING TO CELL SURFACES: IMPLICATIONS FOR XENOTRANSPLANTATION. <i>Transplantation</i> , 2001, 71, 440-446.	1.0	14
100	Naturally occurring anti-galactosyl antibodies: relationship to xenoreactive anti-galactosyl antibodies. <i>Glycobiology</i> , 1999, 9, 865-873.	2.5	43
101	Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues. <i>Journal of Clinical Immunology</i> , 1999, 19, 116-126.	3.8	38
102	Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. <i>Journal of Clinical Immunology</i> , 1997, 17, 311-321.	3.8	51
103	Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. <i>Journal of Immunology</i> , 1996, 157, 5163-8.	0.8	59